Peptide-Based Vaccines and Therapeutics for COVID-19.

Pritam V Bagwe, Priyal V Bagwe, Sai Srinivas Ponugoti, Shreerang V Joshi
Author Information
  1. Pritam V Bagwe: Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, Maharashtra 400019 India.
  2. Priyal V Bagwe: Vaccine Nanotechnology Laboratory, Center for Drug Delivery and Research, College of Pharmacy, Mercer University, Atlanta, GA 30341 USA.
  3. Sai Srinivas Ponugoti: Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, Maharashtra 400019 India.
  4. Shreerang V Joshi: Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, Maharashtra 400019 India. ORCID

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been prevalent in the humans since 2019 and has given rise to a pandemic situation. With the discovery and ongoing use of drugs and vaccines against SARS-CoV-2, there is still no surety of its complete suppression of this disease or if there is a need for additional booster doses. There is an urgent need for alternative treatment strategies against COVID-19. Peptides and peptidomimetics have several advantages as therapeutic agents because of their target selectivity, better interactions, and lower toxicity. Minor structural alterations to peptides can help prevent their fast metabolism and provide long-action. This comprehensive review provides an overview of different peptide-based vaccines and therapeutics against SARS-CoV-2. It discusses the design and mechanism of action of the peptide-based vaccines, peptide immunomodulators, anti-inflammatory agents, and peptides as entry inhibitors of SARS-CoV-2. Moreover, the mechanism of action, sequences and current clinical trial studies are also summarized. The review also discusses the future aspects of peptide-based vaccines and therapeutics for COVID-19.
Graphical Abstract:

Keywords

References

  1. J Hepatol. 2016 Sep;65(3):483-9 [PMID: 27132172]
  2. Int J Mol Sci. 2020 Dec 15;21(24): [PMID: 33333996]
  3. Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81 [PMID: 16081529]
  4. J Chem Phys. 2020 Aug 21;153(7):075101 [PMID: 32828084]
  5. Intervirology. 2018;61(4):166-173 [PMID: 30654366]
  6. Nat Commun. 2021 Mar 9;12(1):1517 [PMID: 33750821]
  7. Clin Transl Immunology. 2019 Aug 05;8(8):e1073 [PMID: 31406574]
  8. Nature. 2020 Aug;584(7821):437-442 [PMID: 32555388]
  9. Immunol Res. 2014 Aug;59(1-3):118-28 [PMID: 24845462]
  10. Virology. 2006 Jun 20;350(1):15-25 [PMID: 16510163]
  11. N Engl J Med. 2020 Mar 26;382(13):1199-1207 [PMID: 31995857]
  12. Mol Divers. 2021 Feb;25(1):625-659 [PMID: 32880078]
  13. Microb Pathog. 2020 Aug;145:104236 [PMID: 32376359]
  14. Biochem J. 2013 Jun 1;452(2):331-43 [PMID: 23527573]
  15. Nat Rev Drug Discov. 2021 Apr;20(4):309-325 [PMID: 33536635]
  16. Arch Med Res. 2020 Oct;51(7):608-612 [PMID: 32682575]
  17. Mol Cell. 2020 May 21;78(4):779-784.e5 [PMID: 32362314]
  18. Nat Rev Immunol. 2021 Jun;21(6):382-393 [PMID: 33875867]
  19. Sci Rep. 2020 Nov 24;10(1):20465 [PMID: 33235258]
  20. Autoimmun Rev. 2020 Jul;19(7):102562 [PMID: 32376400]
  21. Curr Opin Chem Biol. 2008 Jun;12(3):292-6 [PMID: 18423417]
  22. J Gen Virol. 2001 Jun;82(Pt 6):1375-1386 [PMID: 11369882]
  23. Inflamm Res. 2019 Feb;68(2):125-145 [PMID: 30560372]
  24. Med J Armed Forces India. 2020 Oct;76(4):370-376 [PMID: 32895599]
  25. Front Immunol. 2020 Nov 09;11:577442 [PMID: 33240265]
  26. Nat Rev Microbiol. 2009 Mar;7(3):226-36 [PMID: 19198616]
  27. Antiviral Res. 2006 Feb;69(2):70-6 [PMID: 16337697]
  28. BMJ Open. 2024 Mar 15;14(3):e076142 [PMID: 38490660]
  29. Biochem Biophys Res Commun. 2005 Jan 21;326(3):554-63 [PMID: 15596135]
  30. Viruses. 2019 Aug 01;11(8): [PMID: 31374901]
  31. Expert Rev Anti Infect Ther. 2021 Oct;19(10):1205-1217 [PMID: 33844613]
  32. Int J Mol Sci. 2018 Sep 11;19(9): [PMID: 30208640]
  33. BMJ. 2014 Mar 25;348:g2317 [PMID: 24668837]
  34. Vaccine. 2020 Jun 9;38(28):4464-4475 [PMID: 32418793]
  35. Nat Med. 2021 Dec;27(12):2127-2135 [PMID: 34650248]
  36. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93 [PMID: 15897467]
  37. Front Pharmacol. 2020 Sep 15;11:575444 [PMID: 33041819]
  38. Clin Infect Dis. 2020 Nov 19;71(16):2150-2157 [PMID: 32442287]
  39. J Diabetes Complications. 2020 Dec;34(12):107723 [PMID: 32900588]
  40. Nat Commun. 2020 Aug 25;11(1):4252 [PMID: 32843628]
  41. Nature. 2020 May;581(7807):221-224 [PMID: 32225175]
  42. Curr Top Med Chem. 2021;21(7):571-596 [PMID: 33463470]
  43. J Pathol. 2004 Jun;203(2):631-7 [PMID: 15141377]
  44. Ther Deliv. 2013 Nov;4(11):1443-67 [PMID: 24228993]
  45. PLoS Pathog. 2021 Feb 4;17(2):e1009312 [PMID: 33539432]
  46. Med Hypotheses. 2020 Nov;144:110284 [PMID: 33245278]
  47. Clin Rheumatol. 2020 Jul;39(7):2085-2094 [PMID: 32474885]
  48. Science. 2020 Oct 23;370(6515):426-431 [PMID: 32907861]
  49. Nat Microbiol. 2020 Apr;5(4):536-544 [PMID: 32123347]
  50. J Med Chem. 2010 Feb 11;53(3):1067-75 [PMID: 20038105]
  51. Brief Bioinform. 2021 Mar 22;22(2):1309-1323 [PMID: 33285567]
  52. Science. 2020 Mar 27;367(6485):1444-1448 [PMID: 32132184]
  53. J Immunol Res. 2021 Jun 02;2021:9944880 [PMID: 34124273]
  54. Front Immunol. 2019 Jun 21;10:1366 [PMID: 31293570]
  55. Proteins. 2005 Apr 1;59(1):72-9 [PMID: 15688445]
  56. J Virol. 2019 Mar 5;93(6): [PMID: 30626688]
  57. Nat Commun. 2020 Mar 27;11(1):1620 [PMID: 32221306]
  58. Natl Sci Rev. 2020 Jun;7(6):998-1002 [PMID: 34676125]
  59. Front Pharmacol. 2020 Dec 03;11:578382 [PMID: 33343349]
  60. ACS Cent Sci. 2020 Oct 28;6(10):1722-1734 [PMID: 33140034]
  61. J Biol Chem. 2019 Apr 12;294(15):5736-5746 [PMID: 30696772]
  62. Biomed Res Int. 2020 May 11;2020:2683286 [PMID: 32461973]
  63. Nat Rev Drug Discov. 2007 May;6(5):404-14 [PMID: 17473845]
  64. Int J Biol Sci. 2020 Mar 15;16(10):1753-1766 [PMID: 32226295]
  65. Cell. 2020 Apr 16;181(2):271-280.e8 [PMID: 32142651]
  66. Nat Commun. 2020 Jun 1;11(1):2806 [PMID: 32483236]
  67. Cytokine. 2020 Sep;133:155151 [PMID: 32544563]
  68. Eur J Intern Med. 2020 Jun;76:14-20 [PMID: 32336612]
  69. Sci Rep. 2020 Aug 26;10(1):14214 [PMID: 32848162]
  70. Nature. 2020 May;581(7807):215-220 [PMID: 32225176]
  71. Nature. 2020 Jul;583(7816):459-468 [PMID: 32353859]
  72. J Virol. 2008 Sep;82(17):8887-90 [PMID: 18562523]
  73. J Biomol Struct Dyn. 2022 Aug;40(12):5566-5576 [PMID: 33438525]
  74. Expert Rev Anti Infect Ther. 2022 Mar;20(3):373-381 [PMID: 34348067]
  75. Life Sci Alliance. 2020 Jul 23;3(9): [PMID: 32703818]
  76. Cell. 2020 May 14;181(4):894-904.e9 [PMID: 32275855]

Word Cloud

Created with Highcharts 10.0.0vaccinesSARS-CoV-2peptidesCOVID-19peptide-basedPeptideneedagentsreviewtherapeuticsdiscussesactionalsoSevereacuterespiratorysyndromecoronavirus2prevalenthumanssince2019givenrisepandemicsituationdiscoveryongoingusedrugsstillsuretycompletesuppressiondiseaseadditionalboosterdosesurgentalternativetreatmentstrategiesPeptidespeptidomimeticsseveraladvantagestherapeutictargetselectivitybetterinteractionslowertoxicityMinorstructuralalterationscanhelppreventfastmetabolismprovidelong-actioncomprehensiveprovidesoverviewdifferentdesignmechanismpeptideimmunomodulatorsanti-inflammatoryentryinhibitorsMoreoverthe mechanismsequencescurrentclinicaltrialstudiessummarizedfutureaspectsGraphicalAbstract:Peptide-BasedVaccinesTherapeuticsAnti-inflammatoryEntryinhibitingimmunemodulatorstherapies

Similar Articles

Cited By